Our research benefits from an external network of more than 300 academic and 100 industry alliances focused on areas of mutual scientific interest.
Collaborations can boost efficiency and accelerate progress by facilitating access to ideas, capabilities and talent not always available within our walls. By joining forces with external innovators to pursue shared scientific interests, we can increase the breadth and depth of the science that we cover.
Our Strategic Alliances, Operational Alliances and Academic Relations teams work with prospective partners to establish collaborations that are mutually beneficial and productive. We remain actively engaged with our collaborators to ensure a productive collaboration environment and maximize the probability of success.
The Strategic Alliances team is flexible in structuring deals and aims to tailor our collaborations to each partner’s individual needs. Deal types include in-licensing, out-licensing/risk-sharing, research collaborations, options, equity investments and acquisitions.
“We are always looking for collaborators who are working on breakthrough science, and we try to match their hopes and aspirations with ours,” says Martin Seidel, Vice President and Global Head of Strategic Alliances at the Novartis Institutes for BioMedical Research (NIBR).
We have already teamed up with leading academic experts and biotechnology companies in fields such as oncology, immuno-oncology, regenerative medicine, neuroscience and immunology.
Collaborations help energize emerging fields of biomedicine. We were the first major pharmaceutical company to announce an alliance to advance chimeric antigen receptor (CAR) T cell therapies for cancer through our collaboration with the University of Pennsylvania. More recently, we teamed up with scientists from Intellia Therapeutics to explore potential medical uses of CRISPR/Cas9 genome-editing technologies, with Novartis again being the first major pharma to strike a therapeutics-focused deal in this emerging area of science. Both CRISPR and CART technologies have since become areas of widespread interest in the biomedical and biotech community.
Building success together
We seek collaborations that:
Support breakthrough science in academic labs focused on research of mutual interest
Access new biological insights, innovative drug discovery technologies and novel drug modalities and drug-delivery approaches
Gain access to drug discovery programs and drug candidates that seek to address significant unmet medical need
Explore science outside the current internal strategy that have the potential to set future biomedical directions for Novartis
Our Strategic Alliances team seeks collaborations in most therapeutic areas and technology classes (see chart below), from idea-generation and early discovery through clinical proof-of-concept (phase IIa clinical trials).
“If someone wishes to fully exploit the scientific and medical potential of their program and to find its best and broadest areas of application, Novartis can put the appropriate resources and muscle behind the task,” says Seidel. “And should a program advance to the market, Novartis also has the network and capabilities to maximize the commercial opportunity. We are a global company with global reach.”